OCS

Oculis Holding (OCS) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.

Markets

Oculis Stock Slides 4%, Wiping Out $18 Million, After Setting Up Share Sale Program

The eye-drug developer can now sell up to $125 million of new shares over time, a day after it posted third-quarter results.

SEC Filings

Oculis Nine-Month Loss Narrows To CHF 57.1 Million, Helped By A Warrant Gain, As Dry Eye Readout Nears

Cash of $252.0 million is meant to last into the second half of 2029, and the dry eye trial's topline results are due around year-end.